Clinical evaluation of the effectiveness of meloxivet in the complex treatment of cats with mammary gland carcinoma

Abstract

This study presents the results of a clinical administration of meloxivet nonsteroidal anti-inflammatory treatment against the background of the docetaxel + cyclophosphamide regimen chemotherapy following bilateral mastectomy in cats with mammary gland carcinoma. The inclusion of meloxivet in complex chemotherapy against breast carcinomas bilateral mastectomy improved treatment results. In particular, survival was extended in the clinical stages: I and II - by 1.3 times, III - by 1.6 times, and the disease-free period was increased by 1.5, 1.4 and 1.9 times, respectively. Complex treatment of cats including non-steroidal anti-inflammatory therapy reduced the risk of disease progression depending on the clinical stage during the first six months after the end of the course. An increase in the number of patients with subsequent metastasis (after six to twelve months) was also noted. The use of meloxivet made it possible to avoid disease progression in cats up to three years of age, and to reduce its probability and delay the onset of metastasis in all age categories. The proposed scheme of treatment of cats with mammary gland carcinomas reduced side effects, indicating an insignificant risk of negative effects of long-term meloxivet use against the background of a 1.5- fold reduction in the frequency of recurrences in the surgical intervention area.